Senescence-Associated Secretory Phenotypes Reveal Cell-Nonautonomous Functions of Oncogenic RAS and the p53 Tumor Suppressor
Open accessThe DOI matches its Crossref record; 82 of the 82 references it cites were found in a registry or an index; 25 of the 72 sources its claims cite were checked for support.
Abstract
Cellular senescence suppresses cancer by arresting cell proliferation, essentially permanently, in response to oncogenic stimuli, including genotoxic stress. We modified the use of antibody arrays to provide a quantitative assessment of factors secreted by senescent cells. We show that human cells induced to senesce by genotoxic stress secrete myriad factors associated with inflammation and malignancy. This senescence-associated secretory phenotype (SASP) developed slowly over several days and only after DNA damage of sufficient magnitude to induce senescence. Remarkably similar SASPs developed in normal fibroblasts, normal epithelial cells, and epithelial tumor cells after genotoxic stress in culture, and in epithelial tumor cells in vivo after treatment of prostate cancer patients with DNA-damaging chemotherapy. In cultured premalignant epithelial cells, SASPs induced an epithelial-mesenchyme transition and invasiveness, hallmarks of malignancy, by a paracrine mechanism that depended largely on the SASP factors interleukin (IL)-6 and IL-8. Strikingly, two manipulations markedly amplified, and accelerated development of, the SASPs: oncogenic RAS expression, which causes genotoxic stress and senescence in normal cells, and functional loss of the p53 tumor suppressor protein. Both loss of p53 and gain of oncogenic RAS also exacerbated the promalignant paracrine activities of the SASPs. Our findings define a central feature of genotoxic stress-induced senescence. Moreover, they suggest a cell-nonautonomous mechanism by which p53 can restrain, and oncogenic RAS can promote, the development of age-related cancer by altering the tissue microenvironment.
Overview
CoChat Summary
TL;DR
Senescent human fibroblasts and epithelial cells develop a complex senescence-associated secretory phenotype (SASP) that can promote malignant phenotypes in neighboring cells, including epithelial–mesenchymal transition (EMT) and invasion. Oncogenic RAS and loss of p53 amplify and accelerate this SASP, suggesting p53 acts as a cell-nonautonomous tumor suppressor by restraining protumorigenic secreted factors.
Key findings
- Of 120 proteins assayed, 41 were significantly oversecreted by senescent cells compared with presenescent cells, while 79 showed no significant difference; the SASP included inflammatory cytokines/chemokines, growth factors, shed surface molecules, and survival factors.
- The SASP was conserved across cell types: normal fibroblasts and normal prostate epithelial cells overlapped significantly (p ≈ 10⁻³; r = 0.53; >66% overlap), and 24 proteins were shared between all fibroblast and all epithelial SASPs (p ≈ 10⁻⁵).
- SASP induction required genotoxic stress sufficient to cause senescence: 10 Gy X-irradiation induced a SASP, whereas 0.5 Gy did not; the SASP developed slowly, requiring 4–7 d after irradiation.
- Oncogenic RAS induced an amplified SASP: correlations with REP/XRA SASPs were 0.75 for WI-38/IMR-90 and 0.84 for HCA-2 fibroblasts; nine proteins were significantly more secreted in SEN(RAS) versus SEN(REP;XRA) across all fibroblasts, plus five RAS-unique proteins.
- p53 loss was not required to initiate or maintain a SASP, but it amplified it: a subset of SASP proteins was secreted at 5- to 30-fold higher levels after p53 inactivation, and combined p53 loss plus oncogenic RAS produced the most amplified SASP, with accelerated development within 2–4 d.
- SASP factors induced EMT and invasion in nonaggressive breast cancer cells; IL-6 and IL-8 blocking antibodies reduced SEN CM–stimulated invasion.
- In human prostate cancer biopsies after mitoxantrone chemotherapy, tumors showed higher p16INK4a and p21 mRNAs, lower cyclin A, MCM-3, and PCNA mRNAs, and higher mRNAs for IL-6, IL-8, GM-CSF, GRO-α, IGFBP-2, and IL-1β, while IL-2 mRNA did not significantly change.
Methods
- Human fibroblast strains (WI-38, IMR-90, BJ, HCA2, hBF184), normal prostate epithelial cells (PrECs), and prostate tumor lines (BPH1, RWPE1, PC3) were induced to senesce by replicative exhaustion (REP), 10 Gy X-irradiation (XRA), oncogenic RAS, or mitoxantrone (MIT); p53 was inactivated using GSE22 or shRNA.
- Conditioned media were analyzed with modified antibody arrays detecting 120 proteins, using ³⁵S-streptavidin detection for improved dynamic range; findings were validated by ELISA, immunostaining, invasion assays, and RT-PCR.
- Human prostate cancer biopsies were obtained before and after MIT chemotherapy; approximately 1,000 tumor epithelial cells were laser-captured per sample, and mRNA was quantified by RT-PCR. Statistical analyses used Pearson correlation, two-tailed Student t-test, and hypergeometric distribution for SASP overlap.
Limitations
- The paper does not include a formal limitations section.
- Evident from the text: the in vivo human SASP evidence relies on mRNA from laser-captured tumor cells rather than direct measurement of secreted proteins, with approximately 1,000 cells captured per sample.
- Evident from the text: many mechanistic conclusions come from cultured cells, and the SASP is described as not a fixed phenotype, with quantitative and qualitative differences among cell strains, tissues, and donors.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Figures


![Figure 3 Chemotherapy-Induced SASP in Culture and In Vivo (A) Overall correlation between XRA and mitoxantrone (MIT)-induced SASPs for all three prostate epithelial cancer cell lines (BPH-1, RWPE-1, and PC-3). Correlations for the individual cell lines are given in the table to the right. The senescence inducer (XRA or MIT) is given in parentheses. (B–E) Human tumor cells were isolated from biopsies obtained from the same patient before MIT chemotherapy and from prostate tissue following prostatectomy after MIT chemotherapy. Laser captured cells were analyzed by quantitative RT-PCR for the mRNAs encoding the indicated proteins, as described in Materials and Methods and Text S1. The results are displayed on a log10 scale indicating the values before (horizontal or x-axis) compared to after (vertical or y-axis) chemotherapy (top left panel in [B]). Each black dot in (B, C, and D) represents the results obtained from a single patient. The average values for all patients before versus after chemotherapy are indicated by a red dot (B–D); these values are also represented as a heat map in (E). (B) Values for mRNAs encoding proteins associated with senescence (p16 and p21) and proliferation (cyclin A, MCM-3, and PCNA). (C) Values for mRNAs encoding SASP-associated proteins (IL-6, IL-8, GM-CSF, GRO-α, IGFBP-2, and IL-1β). (D) Value for an mRNA encoding a non-SASP–associated protein (IL-2). (E) Averages for the values shown in (B–D). Overall p-values, determined by the Student t-test, and number of paired samples (or patients) analyzed for each mRNA are given to the right of the heat map. Signals higher than the prechemotherapy baseline are shown in red; signals below baseline are displayed in green.](https://figures.cochat.ai/paper-figures/92013b1ef9b3492d8c26b76b40577c28/senescence-associated-secretory-phenotypes-reveal-cell-nonautonomous-functions-figure-3.jpg)


![Figure 6 p53 Restrains the SASP (A) CM containing factors secreted by the indicted cells were analyzed by antibody arrays and displayed, using PRE CM as the baseline. We pooled data from cells of the same genotype (p53 wild type or p53 deficient) under the same culture conditions. SEN indicates pooled data from cells originating from the same tissue (WI-38, IMR-90 from embryonic lung; and HCA-2, BJ from neonatal foreskin) and induced to senesce by REP or XRA. Pooling and averaging of highly correlated samples was performed as described for Figure 5, and details of the data processing are provided in Datasets S13–S16. The top four rows are the same top four rows in Figure 5A and are included to serve as a visual reference. The senescence inducer is given in parentheses. p53 status is indicated as either wild type (wt) or deficient (d) owing to either GSE22 expression or expression of an shRNA against p53. Manipulations are indicated in sequence, separated by a greater than symbol (>). The heat map key (right) indicates the log2-fold changes. Signals higher than the baseline are shown in yellow; signals below baseline are displayed in blue. Comparison between rows is accurately illustrated in (B) and (C) in which each genetically manipulated cell type is compared to its appropriate control baseline. (B) Log2-fold values for SASP factors that are significantly increased, or significantly and uniquely (as indicated by double asterisks [**]) elevated, in CM from SEN cells made p53 deficient by GSE22, using untreated wild-type SEN values as the baseline. Green indicates WI-38 cells made senescent by XRA, after which p53 was subsequently inactivated by expressing GSE22 using a lentivirus; these cells do not resume proliferation (“unreverted”) upon p53 inactivation (see Figure S6). Blue indicates WI-38 in which p16 was inactivated by an shRNA, induced to senesce by XRA, then infected with the GSE22-expressing lentivirus; these cells do revert (REV) after p53 inactivation. Pink indicates HCA2 cells made SEN by XRA, then infected with GSE22 lentivirus; these cells also revert after p53 inactivation. (C) Log2-fold values for SASP factors that are significantly increased, or significantly and uniquely (as indicated by double asterisks [**]) elevated, in CM from cells made p53-deficient (by GSE22 expression), then induced to senesce by REP, XRA, or RAS. Red indicates WI-38 and IMR90 (averaged) cells expressing GSE22, then induced to senesce by XRA or REP, using cells made SEN by XRA or REP as a baseline. Gray indicates WI-38, IMR-90, and HCA2 (averaged) expressing GSE22, then made senescent by RAS, using SEN by RAS as a baseline. (D) WI-38 cells expressing GSE22 were induced to senesce by XRA and then immunostained for the SASP proteins IL-6 and IL-8, the senescence marker p16INK4a, and p53, which accumulates in the presence of GSE22. (E) Comparative graphical representation of the secretory profiles of cells made senescent by XRA or REP (dotted line), RAS (black line), p53 inactivation (GSE22) followed by XRA or REP (blue line), or p53 inactivation (GSE22) followed by RAS (red line). The increased slopes (as indicated by the arrow)indicate amplified SASPs. (F) Hierarchical cluster analysis of all the cells analyzed in (A), plus the SASP induced by RAS (see Figure 5). RAS status is indicated as either wild type (wt) or oncogenic (o) owing to expression of Ha-RASv12. (G) WI-38 cells with wild-type (wt) or inactive (GSE) p53 were irradiated or induced to express oncogenic RAS (RAS), and CM was collected 4 or 10 d later. Soluble factors were analyzed by antibody arrays and displayed as described in Figure 1D, using PRE CM as the baseline (black column on the left; see also Figure S5C for details). Signals higher than baseline are shown in yellow; signals below baseline are in blue. n/a, not applicable. (H) Log2-fold values for prostate epithelial cell SASP factors that are significantly or uniquely (as indicated by double asterisks [**]) elevated in CM from p53-deficient cancer cells (PC3, BPH1, and RWPE1) that were induced to senesce by XRA, compared to primary p53 wild-type cells (PrECs) that were induced to senesce by XRA.](https://figures.cochat.ai/paper-figures/ec6066e9173e4732bc7f9d2c5718a2dd/senescence-associated-secretory-phenotypes-reveal-cell-nonautonomous-functions-figure-6.jpg)
![Figure 7 Biological Activities of the Amplified SASP (A) T47D and ZR75.1 cells were incubated with the indicated CM for 3 d and then analyzed for cell scattering, immunostained for the indicated proteins, and analyzed for vimentin and actin levels by western blotting. Controls for the immunofluorescence from the same individual experiment are shown in Figure 4B. The senescence inducer is given in parentheses. p53 status was either wild type or deficient (GSE). Manipulations are indicated in sequence, separated by >. (B) Epithelial cells were incubated with CM from the indicated WI-38 cells and assayed for invasion as described in Materials and Methods and Figure 3C. Double asterisks (**) indicate p < 0.02. Error bars indicate the standard deviation around the mean. (C) Epithelial cells were incubated with CM from the indicated fibroblasts and cell number was determined by cell counting, total protein, or green fluorescent protein (GFP) fluorescence using epithelial cells expressing GFP, as described in [80]. A single asterisks (*) indicates p < 0.05. Error bars indicate the standard deviation around the mean. (D) Model for the cell-nonautonomous activities of oncogenic RAS and the p53 tumor suppressor protein. Oncogenic and genotoxic stress of sufficient magnitude to cause senescence induce a SASP, whereby cells secrete inflammatory cytokines, chemokines, and growth factors that can alter the tissue microenvironment and stimulate malignant phenotypes in nearby cells. Thus, in addition to their well-known cell-autonomous effects, oncogenes can promote cancer cell-nonautonomously by inducing a SASP. Oncogenic and genotoxic stress also activate p53, which suppresses cancer by cell-autonomous mechanisms (promoting repair, or inducing apoptosis or senescence). In addition, p53 suppresses cancer by the cell-nonautonomous effects of suppressing the intensity of the SASP and its deleterious effects.](https://figures.cochat.ai/paper-figures/c8eed762510f438c8789f2db0ec751a6/senescence-associated-secretory-phenotypes-reveal-cell-nonautonomous-functions-figure-7.jpg)
Verification
Claims the paper makes
19 Valid · 4 Not valid · 9 Not checked · 117 Own results and interpretations
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“Lastly, in mice and humans, a senescence response to strong mitogenic signals, such as those delivered by certain oncogenes, prevents premalignant lesions from progressing to malignant cancers [ 16 – 19 ].”
What the sources say
- Not checked — no full text of the sourcecites [16] Collado, 2005, Nature source
- Partly supportedcites [17] Chen, 2005, Nature sourceExperimental — accuracy not yet measured
The Abstract reports that p53-dependent senescence restricts Pten-deficient tumorigenesis in mice, and the human-specimen passage reports senescence staining mainly in prostate hyperplasia or PIN rather than frank tumour (page numbers unavailable). The human observations do not establish that senescence prevents progression, and the experimental finding concerns Pten loss rather than strong mitogenic signals generally. (LLM, conf=0.86)
- Partly supportedcites [18] Michaloglou, 2005, Nature sourceExperimental — accuracy not yet measured
The discussion (Nature, vol. 436, 4 August 2005; page not provided) says the findings support oncogene-induced senescence as a mechanism in humans that limits progression of premalignant lesions. The paper studies human melanocytes and naevi, not mice, and describes limitation of progression rather than categorical prevention. (LLM, conf=0.88)
- Not matchedcites [19] Braig, 2005, Nature
Couldn’t be matched to a paper in Crossref, so it can’t be checked.
states a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
Every source the paper cites for this claim was checked and supports it.
In the paper
“Consistent with this view, senescent cells increase with age in mammalian tissues [ 27 ]”
What the sources say
- Supportedcites [27] Campisi, 2005, Cell source
The “Cellular Senescence and Aging” passage (page not provided) says that cells with characteristics of senescence accumulate with age in multiple tissues from humans and rodents. This supports the claim about mammalian tissues. (LLM, conf=0.94)
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“Senescent cells acquire many changes in gene expression, mostly documented as altered mRNA abundance, including increased expression of secreted proteins [ 33 – 41 ].”
What the sources say
- Partly supportedcites [33] Zhang, 2003, Proc Natl Acad Sci U S A sourceExperimental — accuracy not yet measured
The Results report hundreds of changes in transcript abundance during senescence in human fibroblasts, supporting the claim about altered gene expression measured as mRNA. They identify up-regulated genes encoding membrane-associated proteins, but the passages in our copy do not establish increased expression of secreted proteins; membrane-associated is not the same as secreted. (LLM, conf=0.85)
- Supportedcites [34] Chang, 2002, Proc Natl Acad Sci U S A source
The Results and Discussion report many gene-expression changes in senescent HCT116 cells, measured primarily with RNA-based methods, and specifically identify increased expression of genes for secreted factors. The paper also notes parallels with senescence in normal cells. (LLM, conf=0.92)
- Not checked — no full text of the sourcecites [35] Bavik, 2006, Cancer Res source
- Not checked — no full text of the sourcecites [36] Mason, 2004, Oncogene source
- Not checked — no full text of the sourcecites [37] Wajapeyee, 2008, Cell source
- Not matchedcites [38] Kortlever, 2006, Nat Cell Biol
Couldn’t be matched to a paper in Crossref, so it can’t be checked.
- Not checked — no full text of the sourcecites [39] Parrinello, 2005, J Cell Sci source
- Supportedcites [40] Kuilman, 2008, Cell source
The Results (page not provided) report genome-wide expression analysis showing multiple gene classes upregulated during oncogene-induced senescence, including cytokine and chemokine genes. They also report increased IL-6 and IL-8 expression and secretion of IL-6 by senescent cells, supporting the claim about secreted proteins. (LLM, conf=0.91)
- Supportedcites [41] Acosta, 2008, Cell source
The Discussion (page unavailable) identifies increased production of various secreted proteins as a characteristic of senescent cells. It also reports that CXCR2 and many of its ligands are upregulated during senescence, supporting the claim about changes in expression. (LLM, conf=0.90)
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
The sources with a verdict support this claim; the rest weren’t checked yet, have no full text we could read, or their verdicts aren’t rated yet.
In the paper
“Thus, oncogenes such as RAS, which are known to activate protumorigenic paracrine mechanisms during transformation [ 59 – 61 ], might also exert cell-nonautonomous protumorigenic effects through nontransformed cells during the process of inducing senescence ( Figure 7 D).”
What the sources say
- Supportedcites [59] Ancrile, 2007, Genes Dev source
The citation supports the sentence’s background clause about protumorigenic paracrine mechanisms during RAS-driven transformation. The Abstract says RAS-induced IL6 acts in a paracrine fashion to promote angiogenesis and tumor growth; the Summary likewise describes this effect in RAS-driven tumor cells. The later suggestion about senescence is the citing authors’ own inference, not a finding attributed to this source. (LLM, conf=0.92)
- Supportedcites [60] Yang, 2006, Proc Natl Acad Sci U S A source
The Discussion states that RAS signals to stromal cells through Gro-1, inducing senescence and promoting tumor growth or malignant transformation. The paper’s opening summary also reports that Gro-1-induced senescent fibroblasts promote tumor growth, supporting the proposed cell-nonautonomous effect. Page numbers are not provided in our copy. (LLM, conf=0.92)
- Not checked — no full text of the sourcecites [61] Akhurst, 2001, Trends Cell Biol source
hedgedstates a possible cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“Our results showed that human tumor cells very likely undergo senescence in response to DNA damaging chemotherapy in vivo, as reported for mice [ 49 ].”
What the sources say
- Supportedcites [49] Schmitt, 2002, Cell source
The citation is attached to “as reported for mice,” not to the citing authors’ finding about human tumor cells. The cited paper’s Discussion reports chemotherapy-induced senescence in vivo in a murine lymphoma model; it does not itself establish the human finding. (LLM, conf=0.93)
hedgedstates a possible cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
89 more claims · 3 with their cited sources checked
Create a free account to see all 149 claims and every source verdict.
- Probably not a substantial claim. 18
- It may state two separate claims as one. 41
- Borderline: one of the tests for a substantial claim is unclear. 1
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source doesn’t support the claim as written.
In the citing paper
“the effects of the senescent fibroblasts were due primarily to their secretion of matrix metalloproteinases (MMPs), which are prominent SASP components (32, 94).”
From Aging, Cellular Senescence, and Cancer (2013) · cites this paper as [32]
Checked by a reasoning model — may be wrong.
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Senescent cells are metabolically active and can acquire a pro-inflammatory, tissue-destructive, pro-apoptotic senescence-associated secretory phenotype (SASP) [26]”
From Senolytics decrease senescent cells in humans: Preliminary report from a clinical trial of Dasatinib plus Quercetin in individuals with diabetic kidney disease (2019) · cites this paper as [26]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“although it was robustly induced 7–10 days after cultured MEFs were stimulated to senesce by IR (Coppé et al., 2008)”
From An Essential Role for Senescent Cells in Optimal Wound Healing through Secretion of PDGF-AA (2014) · cites this paper as Coppé et al., 2008
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The SASP is primarily a property of cells that senesce owing to, or accompanied by, genomic damage or epigenomic perturbation.”
From Aging, Cellular Senescence, and Cancer (2013) · cites this paper as [32]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Many types of cytotoxic chemotherapies are severe DNA-damaging agents that can induce senescence in both tumor cells and surrounding normal cells (31–34).”
From Aging, Cellular Senescence, and Cancer (2013) · cites this paper as [32]
Experimental — accuracy not yet measured
80 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
Hanahan, D., & Weinberg, R. A. (2000) · Cell · doi:10.1016/s0092-8674(00)81683-9 · Cited by 29,219
Coussens, L. M., & Werb, Z. (2002) · Nature · doi:10.1038/nature01322 · Cited by 15,111
A biomarker that identifies senescent human cells in culture and in aging skin in vivo.
Dimri, G. P., Lee, X., Basile, G., Acosta, M., Scott, G., Roskelley, C., Medrano, E. E., Linskens, M., Rubelj, I., & Pereira-Smith, O. (1995) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.92.20.9363 · Cited by 7,477
Docetaxel plus Prednisone or Mitoxantrone plus Prednisone for Advanced Prostate Cancer
Tannock, I. F., de Wit, R., Berry, W. R., Horti, J., Pluzanska, A., Chi, K. N., Oudard, S., Théodore, C., James, N. D., Turesson, I., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa040720 · Cited by 5,735 · cited 5×
“We thank R. Driver for support with the array experiments, J. Gray and R. Neve for discussions, cells, and use of Cellomix; A. Huang for help with the microdissection and PCR; A. Zielinski and J. Allison for technical help; T. Beer, M. Garzotto, C. Higano, L. True, R. Vessella, and the University of Washington Medical…”
BackgroundMethodInfluentialOncogenic ras provokes premature cell senescence associated with accumulation of p53 and p16INK4a
Serrano, M., Lin, A. W., McCurrach, M. E., Beach, D., & Lowe, S. W. (1997) · Cell · doi:10.1016/s0092-8674(00)81902-9 · Cited by 5,218 · cited 1×
“prototype [56], induce senescence in part by indirectly”
BackgroundCellular senescence: when bad things happen to good cells
Campisi, J., & d'Adda di Fagagna, F. (2007) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm2233 · Cited by 4,441 · cited 1×
“Several lines of evidence indicate that cellular senescence is a potent tumor-suppressive mechanism [4,9,10].”
BackgroundSelf-citationPleiotropy, natural selection, and the evolution of senescence.
Williams, G. C. (1957) · Evolution · doi:10.1111/j.1558-5646.1957.tb02911.x · Cited by 4,279 · cited 1×
“It is now recognized that aging is a consequence of the declining force of natural selection with age [26,70].”
BackgroundDNA damage response as a candidate anti-cancer barrier in early human tumorigenesis
Bartkova, J., Hořejší, Z., Koed, K., Krämer, A., Tort, F., Zieger, K., Guldberg, P., Sehested, M., Nesland, J. M., Lukas, C., et al. (2005) · Nature · doi:10.1038/nature03482 · Cited by 2,688 · cited 1×
“Moreover, human cells that bypass oncogene-induced senescence [58], as well as cells in some human premalignant lesions [73,74], show signs of a persistently activated DDR.”
BackgroundSenescence and tumour clearance is triggered by p53 restoration in murine liver carcinomas
Xue, W., Zender, L., Miething, C., Dickins, R. A., Hernando, E., Krizhanovsky, V., Cordon-Cardo, C., & Lowe, S. W. (2007) · Nature · doi:10.1038/nature05529 · Cited by 2,473 · cited 1×
“Recent findings show that tumors induced to senesce in mice gradually regress [21,22], owing perhaps to infiltration by cells of the innate immune system [22].”
BackgroundSenescent cells, tumor suppression, and organismal aging: good citizens, bad neighbors
Campisi, J. (2005) · Cell · doi:10.1016/j.cell.2005.02.003 · Cited by 2,379
Research works printed but not linked: 80
- Hanahan, 2000, Cell, 100, 57
- Bissell, 2001, Nature Rev Cancer, 1, 46
- Coussens, 2002, Nature, 420, 860
- Campisi, 2007, Nature Rev Molec Cell Biol, 8, 729
- Dimri, 2005, Cancer Cell, 7, 505
- Ben-Porath, 2004, J Clin Invest, 113, 8
- Chau, 2003, Nature Rev Cancer, 3, 130
- Bargonetti, 2002, Curr Opin Oncol, 14, 86
- Braig, 2006, Cancer Res, 66, 2881
- Campisi, 2003, Nature Rev Canc, 3, 339
- Wright, 2001, Curr Opin Genet Dev, 11, 98
- Collins, 2003, Aging Cell, 2, 145
- Lowe, 2003, Curr Opin Genet Dev, 13, 77
- Ohtani, 2004, J Med Invest, 51, 146
- Gil, 2006, Nature Rev Molec Cell Biol, 7, 667
- Collado, 2005, Nature, 436, 642
- Chen, 2005, Nature, 436, 725
- Michaloglou, 2005, Nature, 436, 720
- Braig, 2005, Nature, 436, 660
- Shay, 2004, Oncogene, 23, 2919
- Ventura, 2007, Nature, 445, 661
- Xue, 2007, Nature, 445, 656
- Donehower, 2002, J Cell Physiol, 192, 23
- Faragher, 2000, Biochem Soc Trans, 28, 221
- Kortlever, 2006, Cell Cycle, 5, 2697
- Kirkwood, 2000, Nature, 408, 233
- Campisi, 2005, Cell, 120, 1
- Price, 2002, Aging Cell, 1, 57
- Vasile, 2001, FASEB J, 15, 458
- Matthews, 2006, Circ Res, 99, 156
- Maier, 2004, Genes Dev, 18, 306
- Tyner, 2002, Nature, 415, 45
- Zhang, 2003, Proc Natl Acad Sci U S A, 100, 3251
- Chang, 2002, Proc Natl Acad Sci U S A, 99, 389
- Bavik, 2006, Cancer Res, 66, 794
- Mason, 2004, Oncogene, 23, 9238
- Wajapeyee, 2008, Cell, 132, 363
- Kortlever, 2006, Nat Cell Biol, 8, 877
- Parrinello, 2005, J Cell Sci, 118, 485
- Kuilman, 2008, Cell, 133, 1019
- Acosta, 2008, Cell, 133, 1006
- Krtolica, 2001, Proc Natl Acad Sci U S A, 98, 12072
- Liu, 2007, Cancer Res, 67, 3117
- Parrinello, 2003, Nat Cell Biol, 5, 741
- Hayward, 1995, In Vitro Cell Dev Biol Anim, 31, 14
- Bello, 1997, Carcinogenesis, 18, 1215
- Kaighn, 1979, Invest Urol, 17, 16
- Chang, 1999, Oncogene, 18, 4808
- Schmitt, 2002, Cell, 109, 335
- Tannock, 2004, N Engl J Med, 351, 1502
- Cowin, 2005, Curr Opin Cell Biol, 17, 499
- Kokkinos, 2007, Cells Tissues Organs, 185, 191
- Dhawan, 2005, J Clin Invest, 115, 1765
- Yuan, 2005, Front Biosci, 10, 853
- Badache, 2001, Cancer Res, 61, 383
- Serrano, 1997, Cell, 88, 593
- Di Micco, 2006, Nature, 444, 638
- Mallette, 2007, Genes Dev, 21, 43
- Ancrile, 2007, Genes Dev, 21, 1714
- Yang, 2006, Proc Natl Acad Sci U S A, 103, 16472
- Akhurst, 2001, Trends Cell Biol, 11, 44
- Beausejour, 2003, EMBO J, 22, 4212
- Ossovskaya, 1996, Proc Natl Acad Sci U S A, 93, 10309
- Mantovani, 2006, Nature Rev Immunol, 6, 907
- Jeyapalan, 2007, Mech Ageing Dev, 128, 36
- Dimri, 1995, Proc Natl Acad Sci U S A, 92, 9363
- Paradis, 2001, Hum Pathol, 32, 327
- Melk, 2003, Kidney Int, 63, 2134
- Bruunsgaard, 2001, Curr Opin Hematol, 8, 131
- Williams, 1957, Evolution, 11, 398
- Roberts, 2006, Eur Spine J, 15, 312
- Herbig, 2006, Science, 311, 1257
- Bartkova, 2005, Nature, 434, 864
- Gorgoulis, 2005, Nature, 434, 907
- Kiaris, 2005, Cancer Res, 65, 1627
- Hill, 2005, Cell, 123, 1001
- Coppe, 2006, J Biol Chem, 281, 29568
- Kaminker, 2005, J Cell Sci, 118, 1321
- Kim, 2004, J Biol Chem, 279, 43799
- Krtolica, 2002, Cytometry, 49, 73
Cited by
Items 901–1,000 of 4,275
mTORC Inhibitors as Broad-Spectrum Therapeutics for Age-Related Diseases
Walters, H. E., & Cox, L. S. (2018) · International Journal of Molecular Sciences · doi:10.3390/ijms19082325 · Cited by 85
“This is thought to underlie the increased occurrence of secondary tumours as a side effect of chemotherapy [11,211,212].”
BackgroundT Cell Immunosenescence in Aging, Obesity, and Cardiovascular Disease
Shirakawa, K., & Sano, M. (2021) · Cells · doi:10.3390/cells10092435 · Cited by 97
“Senescent cells accumulate in organisms with aging and create chronic inflammation in the Cells 2021, 10, 2435. https://doi.org/10.3390/cells10092435 https://www.mdpi.com/journal/cells surrounding tissues via SASP, which causes a functional decline of organs and contributes to the development of multiple age-related c…”
BackgroundInfluentialPotential Regulators of the Senescence-Associated Secretory Phenotype During Senescence and Aging
Han, X., Lei, Q., Xie, J., Liu, H., Li, J., Zhang, X., Zhang, T., & Gou, X. (2022) · The Journals of Gerontology Series A · doi:10.1093/gerona/glac097 · Cited by 110
Underlying Causes and Therapeutic Targeting of the Inflammatory Tumor Microenvironment
Comen, E. A., Bowman, R. L., & Kleppe, M. (2018) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2018.00056 · Cited by 99
Hussong, S. A., Banh, A. Q., Skike, C. E. V., Dorigatti, A. O., Hernandez, S. F., Hart, M. J., Ferrán, B., Makhlouf, H., Gaczynska, M. E., Osmulski, P. A., et al. (2023) · Nature Communications · doi:10.1038/s41467-023-37840-y · Cited by 92
“Accumulation of senescent cells thus creates a proin fl ammatory environment that compromises tissue function 28 .”
Beaupere, C., Garcia, M., Larghero, J., Fève, B., Capeau, J., & Lagathu, C. (2015) · Aging Cell · doi:10.1111/acel.12308 · Cited by 85
“In accordance, senescent cells secrete proinflammatory cytokines and chemokines (such as IL-8 and IL-6) representative of a senescenceassociated secretory phenotype (Coppe et al., 2008).”
BackgroundJiang, W., Liu, H., Wan, R., Wu, Y., Shi, Z., & Huang, W. (2021) · Ageing Research Reviews · doi:10.1016/j.arr.2021.101315 · Cited by 92
Cellular Senescence in the Lung: The Central Role of Senescent Epithelial Cells
Hansel, C., Jendrossek, V., & Klein, D. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21093279 · Cited by 93
“Beside this age-related or stress-induced replicative senescence observed in lungs, stress-induced premature senescence independently of telomere shortening can be induced upon exposure of several stressors: oncogene activation, loss and/or activation of tumor suppressors, DNA damage, ROS and mitochondrial dysfunction…”
BackgroundCXC-Type Chemokines Promote Myofibroblast Phenoconversion and Prostatic Fibrosis
Gharaee‐Kermani, M., Kasina, S., Moore, B. B., Thomas, D. G., Mehra, R., & Macoska, J. A. (2012) · PLoS ONE · doi:10.1371/journal.pone.0049278 · Cited by 92
Shelterin Complex at Telomeres: Implications in Ageing
Mir, S. M., Tehrani, S. S., Goodarzi, G., Jamalpoor, Z., Asadi, J., Khelghati, N., Qujeq, D., & Maniati, M. (2020) · Clinical Interventions in Aging · doi:10.2147/cia.s256425 · Cited by 118
“forms of damage accumulation overtime in an old organism, including DNA damage and oxidative modifications.(10) One of the most significant markers of ageing in both microorganisms and senescent cells are short telomeres.”
BackgroundTsuji, S., Minami, S., Hashimoto, R., Konishi, Y., Suzuki, T., Kondo, T., Sasai, M., Torii, S., Ono, C., Shichinohe, S., et al. (2022) · Nature Aging · doi:10.1038/s43587-022-00170-7 · Cited by 84
Musculoskeletal senescence: a moving target ready to be eliminated
Baar, M. P., Perdiguero, E., Muñoz-Cánoves, P., & de Keizer, P. L. (2018) · Current Opinion in Pharmacology · doi:10.1016/j.coph.2018.05.007 · Cited by 83
“So far, so good, except that senescent cells secrete a broad range of growth factors, pro-inflammatory proteins, and matrix proteinases that alter the microenvironment: The Senescence-Associated Secretory Phenotype (SASP) [14].”
BackgroundWang, Y., Che, L., Chen, X., He, Z., Song, D., Yuan, Y., & Liu, C. (2023) · Bioactive Materials · doi:10.1016/j.bioactmat.2023.01.009 · Cited by 110
Deryabin, P. I., Griukova, A., Nikolsky, N. N., & Borodkina, A. V. (2019) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-019-03374-0 · Cited by 96
“Along with intracellular changes mentioned above, senescent cells secrete a great variety of pro-inflammatory cytokines, chemokines, matrix metalloproteases and growth factors, all together termed senescence-associated secretory phenotype (SASP) [19, 20].”
BackgroundCellular Senescence and Vascular Disease: Novel Routes to Better Understanding and Therapy
Yin, H., & Pickering, J. G. (2016) · Canadian Journal of Cardiology · doi:10.1016/j.cjca.2016.02.051 · Cited by 82
Exploiting tumor cell senescence in anticancer therapy
Lee, M., & Lee, J.-S. (2014) · BMB Reports · doi:10.5483/bmbrep.2014.47.2.005 · Cited by 83
“and IL-8, are secreted from cells that have senesced due to DNA damage, replicative exhaustion, and/or oncogenic insults (55-57).”
BackgroundThe ageing epigenome: Damaged beyond repair?
Sinclair, D. A., & Oberdoerffer, P. (2009) · Ageing Research Reviews · doi:10.1016/j.arr.2009.04.004 · Cited by 83
The Promise of Slow Down Ageing May Come from Curcumin
Sikora, E., Bielak-Zmijewska, A., Mosieniak, G., & Piwocka, K. (2010) · Current Pharmaceutical Design · doi:10.2174/138161210790883507 · Cited by 83
Byun, H.-O., Lee, Y.-K., Kim, J.-M., & Yoon, G. (2016) · BMB Reports · doi:10.5483/bmbrep.2016.49.11.122 · Cited by 83
“such as HGF, FGF, TGF1 and GM-CSF, has also been reported in various types of senescent cells (54, 74).”
BackgroundInfluentialTranslational Horizons in the Tumor Microenvironment: Harnessing Breakthroughs and Targeting Cures
Sun, Y. (2015) · Medicinal Research Reviews · doi:10.1002/med.21338 · Cited by 83
Self-citationTomé, M., Sepúlveda, J. C., Delgado, M., Andrades, J. A., Campisi, J., González, & Bernad, A. (2014) · Stem Cells · doi:10.1002/stem.1699 · Cited by 83
Self-citationAlqahtani, S., Alqahtani, T., Venkatesan, K., Sivadasan, D., Ahmed, R., Sirag, N., Elfadil, H., Mohamed, H. A., A, H., Ahmed, R. E., et al. (2025) · Cells · doi:10.3390/cells14080608 · Cited by 108
“…as cytokines, chemokines, growth factors, proteases The SASP, first described by Coppé et al., 2008, is specifically defined by the secretion of bioactive molecules such as cytokines, chemokines, growth factors, proteases, and extra-cellular vesicles, which influence the tissue microenvironment [9].”
InfluentialMitochondria and cellular senescence: Implications for musculoskeletal ageing
Habiballa, L., Salmonowicz, H., & Passos, J. F. (2019) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2018.10.417 · Cited by 82
Homeostatic nuclear RAGE–ATM interaction is essential for efficient DNA repair
Kumar, V., Fleming, T. H., Terjung, S., Gorzelanny, C., Gebhardt, C., Agrawal, R., Mall, M. A., Ranzinger, J., Zeier, M. G., Madhusudhan, T., et al. (2017) · Nucleic Acids Research · doi:10.1093/nar/gkx705 · Cited by 83
Senescence-Associated MicroRNAs
Munk, R. B., Panda, A. C., Grammatikakis, I., Gorospe, M., & Abdelmohsen, K. (2017) · International review of cytology · doi:10.1016/bs.ircmb.2017.03.008 · Cited by 98
“These reports highlight the extensive functional crosstalk among senescence pathways, inflammation, and disease by MiRNAs that modulate SASP.”
BackgroundInfluentialMitochondrial DNA damage induces apoptosis in senescent cells
Laberge, R.-M., Adler, D., DeMaria, M., Mechtouf, N., Teachenor, R., Cardin, G. B., Desprez, P.-Y., Campisi, J., & Rodier, F. (2013) · Cell Death & Disease · doi:10.1038/cddis.2013.199 · Cited by 82
“in vivo through inflammation and vascularization.(13,14,18,45,46,48) Senescent cells are resistant to apoptosis,”
BackgroundSelf-citationCook, G., Larocca, A., Facon, T. T. F., Zweegman, S., & Engelhardt, M. M. (2020) · Leukemia · doi:10.1038/s41375-020-0918-6 · Cited by 92
“SASP IL-6, IL-8, IL-1, TNFα, b-CHE, CRP, MiRNAs, eHsp72, selenium, Sirt1, PARP1 [53, 79]”
BackgroundInfluentialBiomarkers of aging in frailty and age-associated disorders: State of the art and future perspective
Salvioli, S., Basile, M. S., Bencivenga, L., Carrino, S., Conte, M., Damanti, S., LORENZO, R. D., Fiorenzato, E., Gialluisi, A., Ingannato, A., et al. (2023) · Ageing Research Reviews · doi:10.1016/j.arr.2023.102044 · Cited by 98
Preininger, M. K., & Kaufer, D. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23116217 · Cited by 92
Culberson, J. W., Kopel, J. J., Sehar, U., & Reddy, P. H. (2023) · Ageing Research Reviews · doi:10.1016/j.arr.2023.102001 · Cited by 111
Martínková, E., Maglott, A., Leger, D. Y., Bonnet, D., Stiborová, M., Takeda, K., Martin, S., & Dontenwill, M. (2010) · International Journal of Cancer · doi:10.1002/ijc.25187 · Cited by 81
Robustness and aging—A systems-level perspective
Kriete, A. (2013) · Biosystems · doi:10.1016/j.biosystems.2013.03.014 · Cited by 89
Secretion of microvesicular miRNAs in cellular and organismal aging
Weilner, S., Schraml, E., Redl, H., Grillari-Voglauer, R., & Grillari, J. (2013) · Experimental Gerontology · doi:10.1016/j.exger.2012.11.017 · Cited by 81
“, 2005), and others can promote malignant phenotypes in nearby premalignant cells (Bavik et al., 2006; Coppé et al., 2008; Krtolica et al., 2001; Liu and Hornsby, 2007).”
Protein Acyltransferase DHHC3 Regulates Breast Tumor Growth, Oxidative Stress, and Senescence
Sharma, C., Wang, H.-X., Li, Q., Knoblich, K., Reisenbichler, E., Richardson, A. L., & Hemler, M. E. (2017) · Cancer Research · doi:10.1158/0008-5472.can-17-1536 · Cited by 86
“3B) of proteins (MCP-1, GROa, CXCL16, and IL8) linked to senescence (21).”
BackgroundDemidenko, Z. N., & Blagosklonny, M. V. (2009) · Aging · doi:10.18632/aging.100115 · Cited by 81
“Another hallmark of cellular overactivation in senescent cells is hyper-secretory and proinflammatory phenotype, characterized by production of cytokins, mitogens and proteases [19-26].”
BackgroundExosomes and Other Extracellular Vesicles in HPV Transmission and Carcinogenesis
Guenat, D., Hermetet, F., Prétet, J., & Mougin, C. (2017) · Viruses · doi:10.3390/v9080211 · Cited by 87
“While such a senescence should reduce tumor growth, it favors the release of a broad spectrum of molecules associated with inflammation and malignancy [103].”
BackgroundZhang, H., Xu, J., Long, Y., Maimaitijiang, A., Su, Z., Li, W., & Li, J. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms252312928 · Cited by 108
“Furthermore, p53 regulates the NF-κ B and mTOR signaling pathways and inhibits SASP, thereby alleviating the impact of senescent cells on the microenvironment and suppressing the dissemination of senescence signals [88,93,98–101].”
Salivary Biomarkers for Oral Cancer Detection: An Exploratory Systematic Review
Alcalde, D. E. B., Maturana, A., Marín, C. C. N., Martínez, R., & Niklander, S. E. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25052634 · Cited by 111
“IL-6 is considered and oncogenic cytokine, similar to IL-1 and IL-8, and is reported to cause EMT [86], induce angiogenesis and tumor growth [87,88], disrupt cell–cell communication, impede macrophage function, and promote epithelial and endothelial cell migration and invasion [89].”
BackgroundImpact of aging on the pathophysiology of dry eye disease: A systematic review and meta-analysis
Kitazawa, K., Inomata, T., Shih, K. C., Hughes, J. B., Bozza, N., Tomioka, Y., Numa, K., Yokoi, N., Campisi, J., Dana, R., et al. (2022) · The Ocular Surface · doi:10.1016/j.jtos.2022.06.004 · Cited by 102
Self-citationHan, X., Chen, H., Gong, H., Tang, X., Huang, N., Xu, W., Tai, H., Zhang, G., Zhao, T., Gong, C., et al. (2020) · Journal of Biological Chemistry · doi:10.1074/jbc.ra119.010734 · Cited by 80
“The secretion of pro-inflammatory cytokines and other factors is a key feature of senescence, referred to as SASP (15, 16).”
BackgroundMethodFaheem, M. M., Seligson, N. D., Ahmad, S. M., Rasool, R. U., Gandhi, S. G., Bhagat, M., & Goswami, A. (2020) · Cell Death Discovery · doi:10.1038/s41420-020-0286-z · Cited by 92
Kolesnichenko, M., Mikuda, N., Höpken, U. E., Kärgel, E., Uyar, B., Tufan, A. B., Milanovic, M., Sun, W., Krahn, I., Schleich, K., et al. (2021) · The EMBO Journal · doi:10.15252/embj.2019104296 · Cited by 81
“Activated oncogenes cause DNA strand breaks and induce DDR signaling, thereby promoting cellular senescence similar to cells exposed to DNA-damaging agents (Acosta et al , 2008; Coppe et al , 2008; Kuilman et al , 2008).”
Fan, H., Liu, Z., Paquet, M., Wang, J., Lydon, J. P., DeMayo, F. J., & Richards, J. S. (2009) · Cancer Research · doi:10.1158/0008-5472.can-08-3363 · Cited by 84
Autophagy regulation in preeclampsia: Pros and cons
Nakashima, A., Aoki, A., Kusabiraki, T., Cheng, S., Sharma, S., & Saito, S. (2017) · Journal of Reproductive Immunology · doi:10.1016/j.jri.2017.08.006 · Cited by 90
Consequences of mitotic slippage for antimicrotubule drug therapy
Cheng, B., & Crasta, K. (2017) · Endocrine Related Cancer · doi:10.1530/erc-17-0147 · Cited by 93
Gabuzda, D. H., Jamieson, B. D., Collman, R. G., Lederman, M. M., Burdo, T. H., Deeks, S. G., Dittmer, D. P., Fox, H. S., Funderburg, N., Pahwa, S. G., et al. (2020) · Pathogens and Immunity · doi:10.20411/pai.v5i1.365 · Cited by 89
“Many of these mechanisms also drive induction of senescent cells [126], with a senescence-associated secretory phenotype [SASP] [127] that in turn can elaborate proinflammatory molecules and exacerbate inflammaging [128].”
BackgroundFeliu, N., Kohonen, P. J., Ji, J., Zhang, Y., Karlsson, H. L., Palmberg, L., Nyström, A. M., & Fadeel, B. (2014) · ACS Nano · doi:10.1021/nn5061783 · Cited by 81
“1 was used to test the significance of four distinct senescence-associated gene signatures extracted from the literature.(46) 48 Counts summarized to Ensembl gene models were used for analysis, and only genes with 1 count per million or more in at least three biological replicates were analyzed.”
MethodResultReconstructing the molecular life history of gliomas
Barthel, F. P., Wesseling, P., & Verhaak, R. G. W. (2018) · Acta Neuropathologica · doi:10.1007/s00401-018-1842-y · Cited by 88
“According to our model these cells may be senescent and contribute to the cancer phenotype by eliciting a micro-environment response via SASP.”
BackgroundInfluentialNakamura, M., Ohsawa, S., & Igaki, T. (2014) · Nature Communications · doi:10.1038/ncomms6264 · Cited by 79
Muñoz, D. P., Lee, E. L., Takayama, S., Coppé, J., Heo, S., Boffelli, D., Noia, J. M. D., & Martin, D. I. K. (2013) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1301021110 · Cited by 83
“Because TNFα and TGFβ in combination will induce the EMT in breast cells (42, 51, 52), we asked if EMT-inducing conditions up-regulate AID expression in mammary epithelial cells.”
BackgroundMethodInfluentialSelf-citationXiong, S., Salazar, G., Patrushev, N., Ma, M., Forouzandeh, F., Hilenski, L., & Alexander, R. W. (2013) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/atvbaha.112.301019 · Cited by 79
“A causal relationship between cell senescence and organismal aging has been implied also by observations that senescent cells accumulate in aging organs and disrupt structure and function by paracrine or endocrine secretion of substances inducing pathophysiologic responses.(25) Direct evidence was presented recently t…”
BackgroundKabir, T. D., Leigh, R. J., Tasena, H., Mellone, M., Coletta, R. D., Parkinson, E. K., Prime, S. S., Thomas, G. J., Paterson, I. C., Zhou, D., et al. (2016) · Aging · doi:10.18632/aging.100987 · Cited by 78
“Senescent CAF are likely to predominantly develop from resident fibroblasts in response to micro-environmental insults (such as reactive oxygen species generated by aberrant metabolic activity in cancer cells), as well as those derived from the environment (such as irradiation, chemotherapy and cigarette smoke) and na…”
BackgroundResultIntegrated Multi-Omics for Novel Aging Biomarkers and Antiaging Targets
Wu, L., Xie, X., Liang, T., Ma, J., Yang, L., Yang, J., Li, L., Xi, Y., Li, H., Zhang, J., et al. (2021) · Biomolecules · doi:10.3390/biom12010039 · Cited by 92
Senolytics (DQ) Mitigates Radiation Ulcers by Removing Senescent Cells
Wang, H., Wang, Z., Huang, Y., Zhou, Y., Sheng, X., Jiang, Q., Wang, Y., Luo, P., Luo, M., & Shi, C. (2020) · Frontiers in Oncology · doi:10.3389/fonc.2019.01576 · Cited by 78
“Cellular senescence is not just a state of proliferation inhibition and genetic alteration (10); senescent cells can secrete cytokines, called the senescence-associated secretory phenotype (SASP) including inflammatory factors (11, 12), tissue-reconstituted proteases, and growth factors, which can induce persistent ch…”
BackgroundMitochondrial quality control in AMD: does mitophagy play a pivotal role?
Hyttinen, J. M. T., Viiri, J., Kaarniranta, K., & Błasiak, J. (2018) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-018-2843-7 · Cited by 88
Increased Infiltrated Macrophages in Benign Prostatic Hyperplasia (BPH)
Wang, X., Lin, W., Izumi, K., et al. (2012) · Journal of Biological Chemistry · doi:10.1074/jbc.m112.355164 · Cited by 78
“Especially, among CC-type chemokines, CCL3 has been shown to be important for senescence regulation (28), which is also an important mechanism for BPH development (27).”
BackgroundIncorporating Biomarkers Into Cancer and Aging Research
Hubbard, J. M., Cohen, H. J., & Muss, H. B. (2014) · Journal of Clinical Oncology · doi:10.1200/jco.2014.55.4261 · Cited by 80
MicroRNA controls of cellular senescence
Suh, N. (2018) · BMB Reports · doi:10.5483/bmbrep.2018.51.10.209 · Cited by 78
Carroll, J. E., Bower, J. E., & Ganz, P. A. (2022) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-021-00580-3 · Cited by 76
Using SERS Tags to Image the Three‐Dimensional Structure of Complex Cell Models
de Aberasturi, D. J., Henriksen‐Lacey, M., Litti, L., Langer, J., & Liz‐Marzán, L. M. (2020) · Advanced Functional Materials · doi:10.1002/adfm.201909655 · Cited by 81
Immune response to RB1-regulated senescence limits radiation-induced osteosarcoma formation
Kansara, M., Leong, H. S., Lin, D. M., Popkiss, S., Pang, P., Garsed, D. W., Walkley, C. R., Cullinane, C., Ellul, J., Haynes, N. M., et al. (2013) · Journal of Clinical Investigation · doi:10.1172/jci70559 · Cited by 77
“We and others (17, 43, 44) describe a SASP that includes IL-1β, IL-6, IL-8, and MCP-1.”
BackgroundBuganim, Y., Solomon, H., Rais, Y., Kistner, D., Nachmany, I., Brait, M., Madar, S., Goldstein, I., Kalo, E., Adam, N., et al. (2010) · Cancer Research · doi:10.1158/0008-5472.can-09-2661 · Cited by 77
Is cellular senescence an example of antagonistic pleiotropy?
Giaimo, S., & d’Adda di Fagagna, F. (2012) · Aging Cell · doi:10.1111/j.1474-9726.2012.00807.x · Cited by 77
“which can fuel cancer cell proliferation both in vitro and in mouse xenografts (Krtolica et al., 2001; Coppé et al., 2008), can also trigger the innate immune response and contribute to tumour clearance in vivo in mouse models (Xue et al.”
BackgroundInfluentialBustos, S. O., Antunes, F., Rangel, M. C., & Chammas, R. J. (2020) · Frontiers in Oncology · doi:10.3389/fonc.2020.606436 · Cited by 82
“Likewise, the loss of p53 function can boost SASP in cells and promote tumor growth (83).”
BackgroundEngineering approaches for RNA-based and cell-based osteoarthritis therapies
DeJulius, C. R., Walton, B. L., Colazo, J. M., d’Arcy, R., Francini, N., Brunger, J. M., & Duvall, C. L. (2024) · Nature Reviews Rheumatology · doi:10.1038/s41584-023-01067-4 · Cited by 92
“Senescent cells adopt a senescence-associated secretory phenotype (SASP) that can be an integral source of soluble factors that drive OA 18 .”
Malavolta, M., Bracci, M., Santarelli, L., Sayeed, M. A., Pierpaoli, E., Giacconi, R., Costarelli, L., Piacenza, F., Basso, A., Cardelli, M., et al. (2018) · Mediators of Inflammation · doi:10.1155/2018/4159013 · Cited by 81
“senescent cells can induce deleterious effects in the microenvironment by damaging neighboring cells, thus facilitating tumor development and aggressiveness [31], mediating paracrine transmission of CS [32], and promoting age-related dysfunctions [25].”
Liu, B., Peng, Z., Zhang, H., Zhang, N., Liu, Z., Xia, Z., Huang, S., Luo, P., & Cheng, Q. (2025) · Molecular Cancer · doi:10.1186/s12943-025-02284-z · Cited by 105
Colucci, M., Zumerle, S., Bressan, S., Gianfanti, F., Troiani, M., Valdata, A., D’Ambrosio, M., Pasquini, E., Varesi, A., Cogo, F., et al. (2024) · Cancer Cell · doi:10.1016/j.ccell.2024.02.004 · Cited by 93
Crescenzi, E., Pacifico, F., Lavorgna, A., Palma, R. D., D’Aiuto, E., Palumbo, G. A., Formisano, S., & Leonardi, A. (2011) · Oncogene · doi:10.1038/onc.2011.1 · Cited by 86
Epigenetic Regulation of Inflammatory Signaling and Inflammation-Induced Cancer
Tan, S. Y. X., Zhang, J., & Tee, W. (2022) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2022.931493 · Cited by 91
Carrière, C., Gore, A. J., Norris, A. M., Gunn, J. R., Young, A. L., Longnecker, D. S., & Korc, M. (2011) · Gastroenterology · doi:10.1053/j.gastro.2011.05.041 · Cited by 76
Age-related bone diseases: Role of inflammaging
Bi, J., Zhang, C., Lu, C., Mo, C., Zeng, J., Yao, M., Jia, B., Liu, Z., Yuan, P., & Xu, S. (2024) · Journal of Autoimmunity · doi:10.1016/j.jaut.2024.103169 · Cited by 93
Centrosome dysfunction: a link between senescence and tumor immunity
Wu, Q., Li, B., Liu, L., Sun, S., & Sun, S. (2020) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-020-00214-7 · Cited by 81
“components of the SASP and can promote invasion of the basement membrane by precancerous epithelial cells.(93) This suggests that IL-8 may connect the ECASP with the SASP.”
BackgroundEpithelial cell senescence: an adaptive response to pre-carcinogenic stresses?
Abbadie, C., Pluquet, O., & Pourtier, A. (2017) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-017-2587-9 · Cited by 82
Coordinate regulation of the senescent state by selective autophagy
Lee, Y., Kim, J., Kim, M.-S., Kwon, Y., Shin, S., Yi, H., Kim, H., Chang, M. J., Chang, C. B., Kang, S.-B., et al. (2021) · Developmental Cell · doi:10.1016/j.devcel.2021.04.008 · Cited by 76
Wang, D., & Jang, D. (2009) · Cancer Research · doi:10.1158/0008-5472.can-09-1976 · Cited by 82
“Recent works have demonstrated that chemokines, cytokines, and growth factors play key roles in oncogene-induced senescence (11-14).”
BackgroundOgata, Y., Yamada, T., Hasegawa, S., Sanada, A., Iwata, Y., Arima, M., Nakata, S., Sugiura, K., & Akamatsu, H. (2021) · Experimental Dermatology · doi:10.1111/exd.14205 · Cited by 76
A functional genetic screen defines the AKT-induced senescence signaling network
Chan, K. T., Blake, S., Zhu, H., Kang, J., Trigos, A. S., Madhamshettiwar, P. B., Diesch, J., Paavolainen, L., Horvath, P., Hannan, R. D., et al. (2020) · Cell Death & Differentiation · doi:10.1038/s41418-019-0384-8 · Cited by 71
Musiani, D., Giambruno, R., Massignani, E., Ippolito, M. R., Maniaci, M., Jammula, S., Manganaro, D., Cuomo, A., Nicosia, L., Pasini, D., et al. (2020) · Cell Reports · doi:10.1016/j.celrep.2019.12.061 · Cited by 73
“Importantly, SASP is also triggered in vivo in response to CDDP and other DNA-damaging chemotherapeutics (Coppé et al., 2008), thus limiting the effectiveness of anticancer therapies that are based on genotoxic stress.”
BackgroundBellei, B., Migliano, E., TEDESCO, M., Caputo, S., Papaccio, F., Lopez, G., & Picardo, M. (2018) · Stem Cell Research & Therapy · doi:10.1186/s13287-018-0956-4 · Cited by 79
Cellular senescence and kidney aging
Rex, N., Melk, A., & Schmitt, R. (2023) · Clinical Science · doi:10.1042/cs20230140 · Cited by 100
“The SASP describes a secretion of proinflammatory cytokines, chemokines, growth factors, and proteases that affect surrounding cells and tissues [39].”
BackgroundImmune Aging and Immunotherapy in Cancer
Kaiser, M., Semeraro, M. D., Herrmann, M., Absenger, G., Gerger, A., & Renner, W. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22137016 · Cited by 84
“These in return can promote tumor progression [23,30,32,33].”
BackgroundBile acid-mediated signaling in cholestatic liver diseases
Zeng, J., Fan, J., & Zhou, H. (2023) · Cell & Bioscience · doi:10.1186/s13578-023-01035-1 · Cited by 84
“SASP is a cellular phenotype characterized by increased secretion of proinflammatory cytokines and chemokines, growth factors, metalloproteinases, and extracellular vesicles [57, 58].”
BackgroundGuan, Y., Zhang, C., Lyu, G., Huang, X., Zhang, X., Zhuang, T., Jia, L., Zhang, L., Zhang, C., Li, C., et al. (2020) · Nucleic Acids Research · doi:10.1093/nar/gkaa858 · Cited by 75
Interleukin-6: Molecule in the Intersection of Cancer, Ageing and COVID-19
Brábek, J., Jakubek, M., Vellieux, F. M. D., Novotný, J., Kolář, M., Lacina, L., Szabó, P., Strnadová, K., Rösel, D., Dvořánková, B., et al. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21217937 · Cited by 78
“At the cellular level, accumulating evidence shows that senescent cells may have deleterious effects on the tissue microenvironment [55].”
BackgroundInfluentialMeyer, P., Maity, P., Burkovski, A., Schwab, J., Müssel, C., Singh, K., Ferreira, F. F., Krug, L., Maier, H. J., Wlaschek, M., et al. (2017) · PLOS Computational Biology · doi:10.1371/journal.pcbi.1005741 · Cited by 75
O’Hagan-Wong, K., Nadeau, S., Carrier-Leclerc, A., Apablaza, F., Hamdy, R. C., Shum‐Tim, D., Rodier, F., & Colmegna, I. (2016) · Oncotarget · doi:10.18632/oncotarget.7690 · Cited by 87
Self-citationTargeting Cell Senescence and Senolytics: Novel Interventions for Age-Related Endocrine Dysfunction
Suda, M., Paul, K. H., Tripathi, U., Minamino, T., Tchkonia, T., & Kirkland, J. L. (2024) · Endocrine Reviews · doi:10.1210/endrev/bnae010 · Cited by 99
Atypical pathways of NF-κB activation and aging
Kriete, A., & Mayo, K. L. (2009) · Experimental Gerontology · doi:10.1016/j.exger.2008.12.005 · Cited by 83
Growth hormone is a cellular senescence target in pituitary and nonpituitary cells
Chesnokova, V., Zhou, C., Ben-Shlomo, A., Zonis, S., Tani, Y., Ren, S.-G., & Melmed, S. K. (2013) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1310589110 · Cited by 81
Tighanimine, K., de Freitas, J. A. N. L. F., Nemazanyy, I., Bankolé, A., Benarroch, D., Brodesser, S., Doré, G. R. G., Robinson, L. J., Bénit, P., Ladraa, S., et al. (2024) · Nature Metabolism · doi:10.1038/s42255-023-00972-y · Cited by 83
“Consistent with published data 37–39 , p53 activation suppressed SASP biomarker IL-1α, IL-6 and CXCL8 expression (Extended Data Fig.”
Targeting senescent cells improves functional recovery after spinal cord injury
Paramos-de-Carvalho, D., Martins, I., Cristóvão, A. M., Dias, A. F., Neves-Silva, D., Pereira, T., Chapela, D., Farinho, A., Jacinto, A., & Saúde, L. (2021) · Cell Reports · doi:10.1016/j.celrep.2021.109334 · Cited by 74
Therapeutic targeting of replicative immortality
Yaswen, P., MacKenzie, K. L., Keith, W. N., Hentosh, P., Rodier, F., Zhu, J., Firestone, G. L., Matheu, A., Carnero, A., Bilsland, A. E., et al. (2015) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2015.03.007 · Cited by 96
Self-citationCellular Senescence and Lung Function during Aging. Yin and Yang
Campisi, J. (2016) · Annals of the American Thoracic Society · doi:10.1513/annalsats.201609-703aw · Cited by 74
Self-citationThe long non-coding RNA MIR31HG regulates the senescence associated secretory phenotype
Montes, M., Lubas, M., Arendrup, F. S., Mentz, B., Rohatgi, N., Tumas, S., Harder, L. M., Skanderup, A. J., Andersen, J., & Lund, A. H. (2021) · Nature Communications · doi:10.1038/s41467-021-22746-4 · Cited by 77
Toste, P. A., Nguyen, A. H., Kadera, B. E., Duong, M., Wu, N., Gawlas, I., Tran, L. M., Bikhchandani, M., Li, L., Patel, S. G., et al. (2016) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-15-0348 · Cited by 74
“Importantly, while the SASP was originally described in the setting of senescence-inducing stimuli, its induction is independent of replicative arrest (28, 29).”
BackgroundIGF-Binding Protein 2 – Oncogene or Tumor Suppressor?
Pickard, A., & McCance, D. J. (2015) · Frontiers in Endocrinology · doi:10.3389/fendo.2015.00025 · Cited by 91
CD36 initiates the secretory phenotype during the establishment of cellular senescence
Chong, M., Yin, T., Chen, R., Xiang, H., Yuan, L., Ding, Y., Pan, C. C., Tang, Z., Alexander, P. B., Li, Q., et al. (2018) · EMBO Reports · doi:10.15252/embr.201745274 · Cited by 81
“Both paracrine signaling and autocrine signaling are known to contribute to the senescent process, and canonical SASP cytokines such as IL-6 and IL-8 cell type-specific differences in the ability of individual SASP components to induce senescence.”
Sasaki, M., Miyakoshi, M., Sato, Y., & Nakanuma, Y. (2013) · Digestive Diseases and Sciences · doi:10.1007/s10620-013-2920-6 · Cited by 76
Kim, H., Chang, J., Iyer, S., Han, L., Campisi, J., Manolagas, S. C., Zhou, D., & Almeida, M. (2019) · Aging Cell · doi:10.1111/acel.12923 · Cited by 74
“…is characterized by a permanent proliferative arrest, and an altered gene expression pattern leading to the production of pro‐inflammatory and matrix‐degrading molecules known as the senescence‐associated secretory phenotype (SASP) (Campisi, 2013; Coppe et al., 2008; Kuilman et al., 2008).”
BackgroundSelf-citation
Metadata
- Authors
- Coppé, J.-P., Patil, C. K., Rodier, F., Sun, Y., Muñoz, D. P., Goldstein, J., Nelson, P. S., Desprez, P.-Y., & Campisi, J.
- Affiliations
- Lawrence Berkeley National Laboratory (US)
- Fred Hutch Cancer Center (US)
- Buck Institute for Research on Aging (US)
- Corresponding author
- Campisi, Judith
- Venue
- PLoS Biology
- Publisher
- Public Library of Science (PLoS)
- Published
- 2008-12-02
- Volume
- 6
- Issue
- 12
- Pages
- e301
- ISSN
- 1544-9173 (ISSN-L)
- 1545-7885
- PMC
- PMC2592359
- OpenAlex
- W239602587
- Cited by
- 302
- References
- 81
- Citations by year
- 2025: 16 · 2024: 29 · 2023: 30 · 2022: 38 · 2021: 49 · 2020: 26 · 2019: 15 · 2018: 12 · 2017: 16 · 2016: 16 · 2015: 11 · 2014: 8 · 2013: 4 · 2012: 9
- FWCI
- 5.19
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Locations
- PLoS Biology (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- University of North Texas Digital Library (University of North Texas) (submittedVersion)
- RePEc: Research Papers in Economics (submittedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- eScholarship (California Digital Library) (submittedVersion)
- Figshare (submittedVersion, cc-by)
- Lawrence Berkeley National Laboratory
- Funders
- Larry L. Hillblom Foundation
- University of Washington
- National Institutes of Health (AG09909, AG017242, CA126540, AG000266)
- National Institute on Aging (R56AG009909, AG017242, AG-09909, R37AG009909, AG000266, P01AG017242, T32AG000266)
- National Cancer Institute (CA126540, CA 97186, U54CA126540, P50CA097186)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cell Biology › Telomeres, Telomerase, and Senescence
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Aging › Genetics, Aging, and Longevity in Model Organisms
- Health Sciences › Medicine › Oncology › Cancer-related Molecular Pathways
- Keywords
- senescence-associated secretory phenotype, cellular senescence, genotoxic stress, oncogenic Ras, p53 tumor suppressor, paracrine signaling, interleukin-6, interleukin-8, epithelial-mesenchymal transition, tumor invasion, prostate cancer chemotherapy, tissue microenvironment, age-related cancer
- MeSH terms
- Adult, Aging, Antineoplastic Agents, Cells, Cultured, Epithelial Cells, Fibroblasts, Humans, Infant, Newborn, Male, Neoplasm Invasiveness, Neoplasms, Phenotype, Prostatic Neoplasms, Genes, ras, Interleukin-6, Tumor Suppressor Protein p53, Interleukin-8, Cellular Senescence, Cell Line, Tumor
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
The claim verdicts this report counts are experimental: their accuracy is not yet measured.
A language model drew the claims from the paper on 2026-09-29, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-09-29 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (gpt-6-sol).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.